Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ott PA et al. - The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to proceed with additional trials of this combination. Thalidomide dose escalation beyond 200 mg/day was limited by unacceptable toxicity. Therefore, this combination does not warrant further investigation.

Related Articles

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09    Relevance Score: 70%

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09    Relevance Score: 70%

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09    Relevance Score: 69%

Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09    Relevance Score: 68%

Metastatic cutaneous malignant melanoma: Spectrum of imaging findings and the role of multimodality imaging
Journal of Medical Imaging and Radiation Oncology (JMIRO), 10/05/09    Relevance Score: 68%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address